Replies to post #95182 on Amarin Corp Plc (AMRN)

[caddiedad]

You are what you write.
Read your last sentence out loud again. If you can show proof of a supposed $15-20 offer in 2012 I'm all ears. It wasn't presented to AMRN or the shareholders. In other words, your hypotheticals don't exist. Pure conjecture and message board talk. You love to surface from the depths during the little streams of red share prices now and then. Zero patience and hot air is not a good combo.

[HDGabor]

M-

It is highly unlikely AMRN will ever see $15 again. Even with 15% RRR it sure isn't gonna approach a $5b valuation.

Because ... ? A lot of other add-on drug with high RRR are available or 15% RRR is meaningless (acc. to you) or ...?

The "out of the ballpark" results are already out of the question since it wasn't stopped at interim.

Unless you are member of the DMC or get a first hand info from the DMC, you do not have any basis behind this. Stopping rule contains PE AND SEs and we do not know the exact reason behind continuation. PE (e.g. RRR 80%) does not overwrite the requirements for SEs.

They could have had $15-$20. $15 was a mere 25% premium from where it was trading so give me a break that they couldn't have gotten at least that if they wanted it. It was in the bag. ... Presumably because AMRN management wanted more than what a BP wanted to offer.

Once for all (not for you only). If any BP was really interested they could submit an offer. Management (JZ) claim does not matter, they could not refuse the submission. They could opine pro or cons about the offer, but the decision should be made by the shareholders. I am not aware of any officially submitted offer from anybody. Again:
- BO offer submission depends on potential buyer only, management could not stop it (refuse the submission)
- management could not refuse any offer, since it is the authority of shareholders

Best,
G

[BioChica]

First off, no one knows the RRR for Reduce-It first review by DMC, but the DMC. As noted by other posters, three other CVD trials noted - including 'Jupiter' continued after DMC review even with high RRR.

I believe Vascepa is mirroring these other trails with high RRR. Jelis is probably not an ideal reference for effects of EPA over time, compared to some other small trials we have seen. The Japanese patients started with high levels of EPA in there blood stream from the start of the trial.

After two years on Vascepa I have lost my belly fat, down to 177 from about 185 or so a couple of years ago.

Controlled wait loss? I still eat a lot...